Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes.
Rates of antibiotic resistance in Pseudomonas aeruginosa are increasing worldwide. The multidrug-resistant (MDR) phenotype in P. aeruginosa could be mediated by several mechanisms including multidrug efflux systems, enzyme production, outer membrane protein (porin) loss and target mutations. Currently, no international consensus on the definition of multidrug resistance exists, making direct comparison of the literature difficult. Inappropriate empirical therapy has been associated with increased mortality in P. aeruginosa infections; delays in starting appropriate therapy may contribute to increased length of hospital stay and persistence of infection. In addition, worse clinical outcomes may be associated with MDR infections owing to limited effective antimicrobial options. This article aims to summarize the contemporary literature on patient outcomes following infections caused by drug-resistant P. aeruginosa. The impact of antimicrobial therapy on patient outcomes, mortality and morbidity; and the economic impact of MDR P. aeruginosa infections will be examined.
Hirsch
Elizabeth B
EB
University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA.
Tam
Vincent H
VH
D000890:Anti-Infective Agents / Q000191:economics / Q000627:therapeutic use*; D016527:Drug Costs; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics; D004359:Drug Therapy, Combination; D005838:Genotype; D017048:Health Care Costs; D006801:Humans; D007902:Length of Stay; D010641:Phenotype; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology / Q000401:mortality; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000235:genetics / Q000472:pathogenicity; D013997:Time Factors; D017211:Treatment Failure; D014774:Virulence
D000890:Anti-Infective Agents